Dr. Mrug is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1717 6th Ave S
Birmingham, AL 35233Phone+1 800-822-8816Fax+1 205-933-4497
Education & Training
- University of Alabama Medical CenterFellowship, Nephrology, 2002 - 2004
- USA HealthResidency, Internal Medicine, 1999 - 2002
- Karlovy University FOMClass of 1995
Certifications & Licensure
- AL State Medical License 2002 - 2024
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 105 citationsSingle-Cell RNA Sequencing Identifies Candidate Renal Resident Macrophage Gene Expression Signatures across Species.Kurt A. Zimmerman, Melissa R. Bentley, Jeremie M. Lever, Zhang Li, David K. Crossman
Journal of the American Society of Nephrology. 2019-04-04 - 74 citationsOverexpression of innate immune response genes in a model of recessive polycystic kidney diseaseMichal Mrug, Jing Zhou, Yong H. Woo, Xiangqin Cui, Alexander J. Szalai
Kidney International. 2008-01-01 - 36 citationsKidney Injury Accelerates Cystogenesis via Pathways Modulated by Heme Oxygenase and ComplementJuling Zhou, Xiaosen Ouyang, Trenton R. Schoeb, Subhashini Bolisetty, Xiangqin Cui
Journal of the American Society of Nephrology. 2012-07-01
Journal Articles
- A Practical Guide for Treatment of Rapidly Progressive ADPKD with TolvaptanRonald D Perrone, Anjay Rastogi, Terry Watnick, Arlene B Chapman, Michal Mrug, Vicente E Torres, Fouad T Chebib, Neera K Dahl, Peter C Harris, Journal of the American Society of Nephrology
Authored Content
- Baseline Total Kidney Volume and the Rate of Kidney Growth Are Associated with Chronic Kidney Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseDecember 2017
Press Mentions
- Otsuka’s JYNARQUE™ (Tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 24th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: